Cardiovascular market: A snapshot - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cardiovascular market: A snapshot

Aug 4, 2001

How often have you heard a person complaining about diabetes? Quite often, right? With increasing level of urbanization, stress index levels have moved in tandem. Diabetes, heart diseases and other life style problems are on the rise. No wonder cardiovascular market is the largest and fastest growing therapeutic segment in the global pharmaceutical market. The global cardiovascular market is estimated to be US$ 46 bn, which is around 10% of the world pharma market and is clocking double-digit growth rates. A patient once afflicted with cardiac problem usually carries the problem through his lifetime and brand switching is lowest in this segment. Cardiovascular segments thus attract larger pie of R&D budget of pharma companies worldwide and new drugs are continually rolled out on a regular basis.

India has the fastest growing diabetes patients, thanks to rapid expansion of urbanization. Statistics rolled out by World Health Organisation predicts in about two decades the number of diabetes patients would leap frog to about 57 m from the current 27 m patients.

The domestic market for cardiovascular segment is estimated to be Rs 9.3 bn, which means a market share of around 7%. The cardiovascular market in India has grown at compounded average rate of 28% in last one decade and has outsmarted all other therapeutic markets.

Cardiovascular Market: Segment wise break-up
Sub-Segment Market Size
(Rs m)
Growth
Rate (%)
Beta Blockers 1,318 23.5
ACE Inhibitors 1,259 13.9
Calcium Channel Blockers 2,026 14.4
Hypotensives 945 32.9
Diuretics 335 36.6
Others 823 14.6

Anti-anginals and Hypotensives are broad sub-segments within the cardiovascular category. Anti-anginals are drugs used to remove blockage in arteries ultimately controlling chest pain. Anti-hypertensives are used to control high blood pressures. Diuretics are used to reduce excess level of sodium salt in the body. Usually, patients are required to use multiple drug/medicines for cardiac therapy and thus pharma companies use various combinations of molecules.

The leading players in cardiovascular therapy are mostly domestic companies like Sun Pharma, Torrent, Cadila and ICI Pharma. Share of MNCs is relatively low and their portfolio consists of relatively older molecules.

Apart from the fact that the segment is provides fast growth rates, the margins in the segment are higher due to very limited DPCO exposure. All this is attracting companies to concentrate on this therapeutic segment. Moreover, considering the lifestyle nature of problems, affordability issue is not a major concern in this segment.

Exports of cardiovascular formulations till date have been relatively marginal in the cardiovascular segment. The silver lining is that generic export market for cardiovascular products might open up for Indian companies in a big way in coming years, as some of the prominent molecules in the segment go off patent. However, to sustain export growth in the long-term companies will have race up their research capabilities.

Considering the lucrative market, the segment has higher chances of MNC’s aggressively launching blockbuster products in India post 2005 (when patent protection would be a reality). So brand positioning and basic research will be the key to success and survival for domestic companies. Domestic companies will have to undertake basic research by choice and compulsion to compete against their international counterparts. Otherwise they better have their ‘pulse’ checked at an earlier date.


Equitymaster requests your view! Post a comment on "Cardiovascular market: A snapshot ". Click here!

  

More Views on News

BIOCON Share Price Up by 5%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

BIOCON share price is trading up by 5% and its current market price is Rs 430. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are BIOCON (up 5.0%) and AUROBINDO PHARMA (up 5.1%). The top losers are SANOFI INDIA (down 0.1%) and ALKEM LABORATORIES (down 1.0%).

ERIS LIFESCIENCES LIMITED Share Price Up by 7%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ERIS LIFESCIENCES LIMITED share price is trading up by 7% and its current market price is Rs 560. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 6.9%) and GLENMARK PHARMA (up 5.2%). The top losers are SANOFI INDIA (down 0.1%) and ALKEM LABORATORIES (down 0.4%).

NATCO PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.5% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

NATCO PHARMA share price is trading up by 5% and its current market price is Rs 898. The BSE HEALTHCARE is up by 2.5%. The top gainers in the BSE HEALTHCARE Index is NATCO PHARMA (up 5.4%). The top losers are SANOFI INDIA (down 0.4%) and AJANTA PHARMA (down 0.6%).

CIPLA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.2% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

CIPLA share price is trading up by 5% and its current market price is Rs 770. The BSE HEALTHCARE is up by 2.2%. The top gainers in the BSE HEALTHCARE Index is CIPLA (up 5.1%). The top losers are SANOFI INDIA (down 0.8%) and AJANTA PHARMA (down 0.8%).

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 10%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 10% and its current market price is Rs 302. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 10.0%). The top losers are CADILA HEALTHCARE (down 0.1%) and APOLLO HOSPITALS (down 0.2%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS